Advertisement
Advertisement
U.S. markets open in 2 hours 48 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Mersana Therapeutics, Inc. (MRSN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
5.04+0.09 (+1.82%)
At close: 04:00PM EDT
4.86 -0.18 (-3.57%)
After hours: 07:13PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close4.95
Open4.92
Bid0.00 x 3000
Ask0.00 x 1400
Day's Range4.85 - 5.12
52 Week Range2.68 - 14.80
Volume2,231,105
Avg. Volume1,262,127
Market Cap488.836M
Beta (5Y Monthly)1.91
PE Ratio (TTM)N/A
EPS (TTM)-2.49
Earnings DateAug 08, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est18.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for MRSN

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Mersana Therapeutics, Inc.
    Analyst Report: Seagen Inc.Seagen (formerly known as Seattle Genetics) is a biotech firm that develops and commercializes therapies to treat cancers. Seagen’s therapies are based on antibody-drug conjugate technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. The company's lead product, Adcetris, has received approval for six indications to treat Hodgkin lymphoma and T-cell lymphoma. Other approved products include Padcev for bladder cancer, Tukysa for breast cancer, and Tivdak for cervical cancer. The company has several other oncology programs in pivotal trials. Seagen also licenses its antibody-drug conjugate technology to several leading biotechnology and pharmaceutical companies.
    Rating
    Fair Value
    Economic Moat
    3 days agoMorningstar
View more
Advertisement
Advertisement